GOP AGs Push For Pulling Mifepristone From Market As Telehealth Abortion Increases

By Cara Smith / August 14, 2025 at 3:06 PM

Over 20 GOP state attorneys general have asked FDA to consider withdrawing mifepristone from the market if the agency is unable to reinstate in-person prescribing protocols -- which would eliminate medication abortion through telehealth -- in light of a controversial, non-peer-reviewed study that anti-abortion advocates allege shows the abortion drug isn’t safe.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.